Literature DB >> 24324307

Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions.

Leena Gharat1, Govind P Rathod, Shilpa Kandalgaonkar.   

Abstract

BACKGROUND: A specific association between cancer and the hemostatic system has been recognized for decades. Fibrinogen degradation product (FDP) is one of the factors, which opposes coagulation causing fibrinolysis. The mechanism of fibrinolysis can be used by the malignant cells to facilitate invasion into surrounding tissues and metastases to distant organs by breaking the fibrin barrier. The coagulation cascade also plays an important role in both the formation of tumour stroma and the promotion of hematogenous metastasis. The present study was undertaken to evaluate the serum FDP levels in individuals without any oral lesions and those with oral premalignant and malignant lesions, and determine whether the estimation of the same can be used as an aid in early diagnosis. MATERIALS &
METHODS: 25 cases each of Leukoplakia, Oral submucous fibrosis and Oral squamous cell carcinomas (OSCC) and normal control cases were selected. The OSCC cases were staged according to the TNM classification. Diagnosis of all cases was confirmed by histopathological examination. The aspirated serum was then subjected to the Thrombo-Wellco test which was used for the biochemical analysis of FDP.
RESULTS: Increased serum FDP levels were seen corresponding to the stage of the OSCC, but no appreciable difference was noted between the histological grades or in cases of premalignant lesions.
CONCLUSIONS: The study demonstrates that FDP levels correlate with the cancer stage and progression. Thus, the estimation of serum FDP levels can be used as a reliable prognostic indicator and as a biologic marker of tumour spread How to cite this article: Gharat L, Rathod GP. Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions. J Int Oral Health 2013; 5(5):65-72.

Entities:  

Keywords:  coagulation; fibrinogen degradation product; fibrinolysis; oral squamous cell carcinoma; tumour marker

Year:  2013        PMID: 24324307      PMCID: PMC3845287     

Source DB:  PubMed          Journal:  J Int Oral Health        ISSN: 0976-1799


  30 in total

1.  Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer.

Authors:  M Ghosh; A R Aroor; M R Raghavan
Journal:  Ann Dent       Date:  1990

Review 2.  Effects of anticoagulants on cancer: heparins.

Authors:  Graham F Pineo; Russell D Hull
Journal:  Cancer Treat Res       Date:  2009

Review 3.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

4.  Role of the tissue factor pathway in the biology of tumor initiating cells.

Authors:  Delphine Garnier; Chloe Milsom; Nathalie Magnus; Brian Meehan; Jeffrey Weitz; Joanne Yu; Janusz Rak
Journal:  Thromb Res       Date:  2010-04       Impact factor: 3.944

5.  Fibrin degradation products in serum and urine in patients with renal carcinoma.

Authors:  S Carlsson; F Linell
Journal:  Scand J Urol Nephrol       Date:  1973

6.  A two-step fibrinogen--fibrin transition in blood coagulation.

Authors:  B Blombäck; B Hessel; D Hogg; L Therkildsen
Journal:  Nature       Date:  1978-10-12       Impact factor: 49.962

Review 7.  The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread.

Authors:  Massimo Franchini; Martina Montagnana; Emmanuel J Favaloro; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2009-10       Impact factor: 4.180

8.  Fibrin degradation products and ovarian tumours.

Authors:  B Astedt; L Svanberg; I M Nilsson
Journal:  Br Med J       Date:  1971-11-20

9.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

Review 10.  Fibrinolytic mechanisms in tumor growth and spreading.

Authors:  T Südhoff; W Schneider
Journal:  Clin Investig       Date:  1992-08
View more
  6 in total

1.  Quantitative proteomic analysis for high-throughput screening of differential glycoproteins in hepatocellular carcinoma serum.

Authors:  Hua-Jun Gao; Ya-Jing Chen; Duo Zuo; Ming-Ming Xiao; Ying Li; Hua Guo; Ning Zhang; Rui-Bing Chen
Journal:  Cancer Biol Med       Date:  2015-09       Impact factor: 4.248

2.  Quantification of Plasma Fibrinogen Degradation Products in Areca Nut Chewers with and without Oral Submucous Fibrosis.

Authors:  Sonia Gupta; Manjunath Sm; Manveen Kaur Jawanda; Achla Bharti
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  Inflammation and chemerin in colorectal cancer.

Authors:  Serpil Erdogan; Fatma Meric Yilmaz; Ozan Yazici; Ahmet Yozgat; Sevilay Sezer; Nuriye Ozdemir; Sema Uysal; Tugrul Purnak; Mehmet Ali Sendur; Ersan Ozaslan
Journal:  Tumour Biol       Date:  2015-12-01

4.  Evaluation of plasma fibrinogen degradation products and total serum protein concentration in oral submucous fibrosis.

Authors:  Megha Kadani; Satish B N V S; Maharudrappa B; Prashant K M; Deepa Hugar; Umesh Allad; Prasanth S Prabhu
Journal:  J Clin Diagn Res       Date:  2014-05-15

5.  Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer.

Authors:  Hsing-Ying Lee; Ni-Yen Yu; Shiang-Hsuan Lee; Hui-Ju Tsai; Chih-Ching Wu; Ju-Chien Cheng; Ding-Ping Chen; Ying-Ru Wang; Ching-Ping Tseng
Journal:  Biomed J       Date:  2019-12-24       Impact factor: 4.910

Review 6.  Plasma fibrinogen degradation products in oral submucous fibrosis.

Authors:  Sonia Gupta; Manveen Kaur Jawanda; Nishant Mehta; Vikram Arora; Vipul Yadav
Journal:  J Int Soc Prev Community Dent       Date:  2015 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.